logo

The first bioactive wound dressing - exploiting the unique wound healing and antimicrobial properties of human collagen VI

Sector: Manufacturing (Industrial) • Location: Sweden

Source: EU Funding & Tenders Portal

Project
Ended

Chronic wounds are a global problem. They severely impair the quality of life for 200 million patients worldwide and generate vast medical costs. It is a problem that will only escalate with the increasing incidence of conditions that impede wound healing, such as diabetes, obesity and vascular disorders. The available wound care options can manipulate one or multiple aspects of the wound environm

Status
Closed
Sector
Manufacturing (Industrial), Commercial, Hospital
Location
Sweden
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about The first bioactive wound dressing - exploiting the unique wound healing and antimicrobial properties of human collagen VI

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “The first bioactive wound dressing - exploiting the unique wound healing and antimicrobial properties of human collagen VI” is an infrastructure initiative in the Manufacturing (Industrial) sector, located in Sweden. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ended

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Chronic wounds are a global problem. They severely impair the quality of life for 200 million patients worldwide and generate vast medical costs. It is a problem that will only escalate with the increasing incidence of conditions that impede wound healing, such as diabetes, obesity and vascular disorders. The available wound care options can manipulate one or multiple aspects of the wound environment but cannot form antibacterial barriers and facilitate healing to a satisfactory level at the same time. Effective wound care products to address both: rapid wound closure and combat of infection are, therefore, urgently needed. Colzyx aims to address the unmet challenges in wound management with its novel wound dressing. Basing on a ground-breaking discovery of wound healing and antimicrobial properties of human collagen VI and parts thereof, Colzyx has developed a product that has the potential to revolutionise wound management and create a new category of bioactive wound dressings. WOUNDCOM uses highly functional molecules that promote wound healing by mimicking natural body mechanisms and at the same time combat bacterial infection. This approach offers significant benefits to patients through reduction of pain and discomfort and accelerated recovery. It will also shorten hospitalisation time and decrease the associated financial burden. This project’s objective is to validate the efficacy and safety of WOUNDCOM and bring it to commercial readiness. The project builds on our SMEi Phase 1 project, which provided a valuable understanding of the current trends and opportunities on the wound management market, targeted users, competitors and potential partnerships. The feasibility study was used to optimise the business plan and prepare a synopsis for the clinical study. Successful evaluation of WOUNDCOM’s in the clinic will enable CE marking and support building the awareness and continued strategic partnerships for product manufacturing, marketing, and distribution.

Location

Country

Sweden

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Manufacturing (Industrial), Commercial, Hospital

Article published date

2025-10-01

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project